Literature DB >> 21660492

Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry.

Walter Ageno1, Giancarlo Agnelli, Davide Imberti, Marco Moia, Gualtiero Palareti, Riccardo Pistelli, Melina Verso.   

Abstract

The prevalence of major risk factors for VTE may differ according to age, gender and clinical presentation. We tested this hypothesis in a large Italian VTE population. MASTER is a multicenter registry aimed to prospectively collect information on a large cohort of patients with acute VTE. The presence of major risk factors was captured by an electronic data network in consecutive patients with objectively confirmed acute VTE. We enrolled 2,119 patients (49.8% men) of whom 424 (20%) <40 years, 529 (25%) between 41 and 60 years, 943 (44.5%) between 61 and 80 years, and 223 (10.5%) >80 years. The prevalence of known risk factors in the four age groups is 63.9, 52.6, 54.6, and 58.3%, respectively (p = 0.002). Immobilization and severe medical disorders are more commonly associated with VTE in patients >80 years, trauma is significantly more common in patients <40 years than in older patient groups. The prevalence of unprovoked events is the highest in patients 41-60 years, and lowest in patients less than 40 years. After logistic regression analysis, patients with pulmonary embolism are more likely to have known risk factors for VTE than patients with deep vein thrombosis at presentation (p = 0.0021), and women are less likely than men to have an unprovoked VTE (p < 0.0001). In conclusion, a substantial proportion of VTE events remain classified as unprovoked. Unprovoked events are more common in middle aged patients, in men, and in patients presenting with deep vein thrombosis.

Entities:  

Mesh:

Year:  2011        PMID: 21660492     DOI: 10.1007/s11739-011-0644-1

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  13 in total

1.  Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale.

Authors:  E Oger
Journal:  Thromb Haemost       Date:  2000-05       Impact factor: 5.249

2.  Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.

Authors:  S Schulman; P Lindmarker; M Holmström; G Lärfars; A Carlsson; P Nicol; E Svensson; B Ljungberg; S Viering; S Nordlander; B Leijd; K Jahed; M Hjorth; O Linder; M Beckman
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

3.  Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'.

Authors:  P O Hansson; L Welin; G Tibblin; H Eriksson
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

4.  Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology.

Authors:  L M Steffen; M Cushman; J M Peacock; S R Heckbert; D R Jacobs; W D Rosamond; A R Folsom
Journal:  J Thromb Haemost       Date:  2009-01-19       Impact factor: 5.824

Review 5.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

6.  Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Clive Kearon; Susan R Kahn; Giancarlo Agnelli; Samuel Goldhaber; Gary E Raskob; Anthony J Comerota
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

7.  Acquired risk factors for deep-vein thrombosis in symptomatic outpatients.

Authors:  A Cogo; E Bernardi; P Prandoni; B Girolami; F Noventa; P Simioni; A Girolami
Journal:  Arch Intern Med       Date:  1994-01-24

Review 8.  The epidemiology of venous thromboembolism.

Authors:  Richard H White
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

9.  The MASTER registry on venous thromboembolism: description of the study cohort.

Authors:  Giancarlo Agnelli; Melina Verso; Walter Ageno; Davide Imberti; Marco Moia; Gualtiero Palareti; Romina Rossi; Riccardo Pistelli
Journal:  Thromb Res       Date:  2007-08-10       Impact factor: 3.944

10.  A prospective study of the incidence of deep-vein thrombosis within a defined urban population.

Authors:  M Nordström; B Lindblad; D Bergqvist; T Kjellström
Journal:  J Intern Med       Date:  1992-08       Impact factor: 8.989

View more
  4 in total

Review 1.  Prevention of venous thromboembolism in acutely ill medical patients after the results of recent trials with the new oral anticoagulants.

Authors:  Davide Imberti; Raffaella Benedetti; Walter Ageno
Journal:  Intern Emerg Med       Date:  2013-07-16       Impact factor: 3.397

2.  Mortality at 30 and 90 days in elderly patients with pulmonary embolism: a retrospective cohort study.

Authors:  Hernan Polo Friz; Mauro Molteni; Davide Del Sorbo; Lorenzo Pasciuti; Matteo Crippa; Giulia Villa; Dario Francesco Meloni; Laura Primitz; Andrea Galli; Magda Rognoni; Luca Cavalieri d'Oro; Guido Arpaia; Claudio Cimminiello
Journal:  Intern Emerg Med       Date:  2014-12-25       Impact factor: 3.397

3.  Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry.

Authors:  Chiara Piovella; Fabio Dalla Valle; Javier Trujillo-Santos; Raffaele Pesavento; Leonor López; Llorenç Font; Reina Valle; Dolores Nauffal; Manuel Monreal; Paolo Prandoni
Journal:  Intern Emerg Med       Date:  2014-05-17       Impact factor: 3.397

Review 4.  Elevated risk of venous thromboembolic events in patients with inflammatory myopathies.

Authors:  Michał Nowak; Katarzyna Królak-Nowak; Aleksandra Sobolewska-Włodarczyk; Jakub Fichna; Marcin Włodarczyk
Journal:  Vasc Health Risk Manag       Date:  2016-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.